CD8+ T cell programming by cytomegalovirus vectors: applications in prophylactic and therapeutic vaccination

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

Vectors based on cytomegalovirus (CMV) represent a novel vaccine platform that maintains high frequencies of non-exhausted effector memory T cells in both CMV sero-positive and sero-negative individuals. In non-human primate models, CMV vectored vaccines provide unprecedented protection against simian immunodeficiency virus (SIV). Moreover, CMV vectors can be genetically altered to program highly diverse CD8+ T cell responses that differ in their epitope targeting including conventional, MHC-I restricted CD8+ T cells as well as unconventional CD8+ T cells restricted by MHC class II or non-polymorphic MHC-E. By modifying cytomegaloviral determinants that control unconventional T cell priming it is possible to uniquely tailor the CD8+ T cell response for each individual disease target in order to maximize prophylactic or therapeutic protection.

Original languageEnglish (US)
Pages (from-to)52-56
Number of pages5
JournalCurrent Opinion in Immunology
Volume47
DOIs
StatePublished - Aug 1 2017

Fingerprint

Cytomegalovirus
Vaccination
T-Lymphocytes
Cytomegalovirus Vaccines
Therapeutics
Simian Immunodeficiency Virus
Primates
Epitopes
Vaccines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

@article{497d40c4581f4ca3aff88f8020585876,
title = "CD8+ T cell programming by cytomegalovirus vectors: applications in prophylactic and therapeutic vaccination",
abstract = "Vectors based on cytomegalovirus (CMV) represent a novel vaccine platform that maintains high frequencies of non-exhausted effector memory T cells in both CMV sero-positive and sero-negative individuals. In non-human primate models, CMV vectored vaccines provide unprecedented protection against simian immunodeficiency virus (SIV). Moreover, CMV vectors can be genetically altered to program highly diverse CD8+ T cell responses that differ in their epitope targeting including conventional, MHC-I restricted CD8+ T cells as well as unconventional CD8+ T cells restricted by MHC class II or non-polymorphic MHC-E. By modifying cytomegaloviral determinants that control unconventional T cell priming it is possible to uniquely tailor the CD8+ T cell response for each individual disease target in order to maximize prophylactic or therapeutic protection.",
author = "Klaus Frueh and Louis Picker",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.coi.2017.06.010",
language = "English (US)",
volume = "47",
pages = "52--56",
journal = "Current Opinion in Immunology",
issn = "0952-7915",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - CD8+ T cell programming by cytomegalovirus vectors

T2 - applications in prophylactic and therapeutic vaccination

AU - Frueh, Klaus

AU - Picker, Louis

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Vectors based on cytomegalovirus (CMV) represent a novel vaccine platform that maintains high frequencies of non-exhausted effector memory T cells in both CMV sero-positive and sero-negative individuals. In non-human primate models, CMV vectored vaccines provide unprecedented protection against simian immunodeficiency virus (SIV). Moreover, CMV vectors can be genetically altered to program highly diverse CD8+ T cell responses that differ in their epitope targeting including conventional, MHC-I restricted CD8+ T cells as well as unconventional CD8+ T cells restricted by MHC class II or non-polymorphic MHC-E. By modifying cytomegaloviral determinants that control unconventional T cell priming it is possible to uniquely tailor the CD8+ T cell response for each individual disease target in order to maximize prophylactic or therapeutic protection.

AB - Vectors based on cytomegalovirus (CMV) represent a novel vaccine platform that maintains high frequencies of non-exhausted effector memory T cells in both CMV sero-positive and sero-negative individuals. In non-human primate models, CMV vectored vaccines provide unprecedented protection against simian immunodeficiency virus (SIV). Moreover, CMV vectors can be genetically altered to program highly diverse CD8+ T cell responses that differ in their epitope targeting including conventional, MHC-I restricted CD8+ T cells as well as unconventional CD8+ T cells restricted by MHC class II or non-polymorphic MHC-E. By modifying cytomegaloviral determinants that control unconventional T cell priming it is possible to uniquely tailor the CD8+ T cell response for each individual disease target in order to maximize prophylactic or therapeutic protection.

UR - http://www.scopus.com/inward/record.url?scp=85024867112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024867112&partnerID=8YFLogxK

U2 - 10.1016/j.coi.2017.06.010

DO - 10.1016/j.coi.2017.06.010

M3 - Review article

C2 - 28734175

AN - SCOPUS:85024867112

VL - 47

SP - 52

EP - 56

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

ER -